An FDA Panel Of Experts Backs J&J COVID Vaccine Booster

Washington, Dec 1: A panel of US health advisers narrowly backed the benefits of a closely watched COVID-19 pill from Merck, setting the stage for a likely authorisation of the first drug that Americans could take at home to treat the virus.

A Food and Drug Administration panel voted 13-10 that the drug’s benefits outweigh its risks, including potential birth defects if used during pregnancy.

The group’s recommendation came after hours of debate about the drug’s modest benefits and potential safety issues. Experts backing the treatment stressed that it should not be used by anyone who is pregnant and called on FDA to recommend extra precautions before the drug is prescribed, including pregnancy tests for women of child-bearing age.

The vote specifically backed the drug for adults with mild-to-moderate COVID-19 who face the greatest risks, including older people and those with conditions like obesity and asthma. Most experts also said the drug shouldn’t be used in vaccinated patients, who weren’t part of the study and haven’t been shown to benefit from the medication.

The FDA isn’t bound by the panel’s recommendation and is expected to make its own decision before year’s end.

The drug, molnupiravir, could provide a much-needed weapon against the virus as colder weather pushes case counts higher and US officials brace for the arrival of the new omicron variant. It is already authorised for emergency use.

Merck hasn’t specifically tested its drug against the new variant but said it should have some potency based on its effectiveness against other strains of coronavirus.

But that uncertainty frustrated many panelists as they grappled with whether to back the treatment for millions of Americans.

“With no data saying it works with new variants I really think we need to be careful about saying that this is the way to go,” said Dr David Hardy of Charles Drew University School of Medicine and Science, who ultimately voted to back the drug.

The panel’s narrow-but-positive recommendation came despite new data from Merck that paint a less compelling picture of the drug’s effectiveness than just a few weeks earlier. (AGENCIES)

Source : https://www.dailyexcelsior.com/fda-panel-backs-first-of-a-kind-covid-19-pill-from-merck/

378
FDA expands COVID boosters to all adults, final hurdle ahead

Source:WDBJ

FDA expands COVID boosters to all adults, final hurdle ahead

FDA clears Modernas and Pfizers Covid vaccine booster shots for all U.S. adults

Source:CNBC

FDA clears Modernas and Pfizers Covid vaccine booster shots for all U.S. adults

FDA expands COVID-19 booster shots to all adults; final decision awaits CDC

Source:Boston.com

FDA expands COVID-19 booster shots to all adults; final decision awaits CDC

WATCH: CDC advisory panel votes approves COVID-19 booster shots for all adults

Source:PBS

WATCH: CDC advisory panel votes approves COVID-19 booster shots for all adults

CDC panel backs expanding COVID-19 booster eligibility to all U.S. adults

Source:The Gazette

CDC panel backs expanding COVID-19 booster eligibility to all U.S. adults

FDA panel narrowly backs COVID-19 pill from Merck

Source:WGN-TV

FDA panel narrowly backs COVID-19 pill from Merck

FDA approves COVID boosters for all adults, final hurdle ahead

Source:WESH

FDA approves COVID boosters for all adults, final hurdle ahead